Search

Czapska Mirella, Babkiewicz Kamila, Pabis Szczepan, Skórzyńska-Dziduszko Katarzyna. Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 / 2), as a new therapeutic approach for patients with type 1 diabetes mellitus. Journal of Education, Health and Sport. 2018;8(12):335-351. eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.2267488 http://ojs.ukw.edu.pl/index.php/johs/article/view/6378 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part b item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eissn 2391-8306 7 © The Authors 2018; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 10.11.2018. Revised: 20.11.2018. Accepted: 14.12.2018. Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 / 2), as a new therapeutic approach for patients with type 1 diabetes mellitus Mirella Czapska1, Kamila Babkiewicz1, Szczepan Pabis2, Katarzyna Skórzyńska-Dziduszko3 1Students Scientific Society at the Department of Human Physiology, Medical University of Lublin 2Departament of Urology University of Rzeszów 3Department of Human Physiology, Medical University of Lublin Sotaglifosine, a complex inhibitor of SGLT1 / 2 cotransporters, as a new therapeutic option for patients with type 1 diabetes Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 / 2), as a new therapeutic approach for patients with type 1 diabetes mellitus Summary Sotagliflozin (SOTA) is a dual inhibitor of SGLT1 and SGLT2 used in adultswith type 1 diabetes.The mechanism of action, based on theinhibition ofboth the SGLT1 and SGLT2 cotransporters, allows simultaneous increase of glucose excretion and slowing down the absorption of glucose in the intestine.Recently, testresults have been publishedshowinga beneficialeffect of sotagliflozin ontype 1 diabetes control[1,2,3]. Sotagliflozin use leads to a significant reduction inglycosylated haemoglobin(HbA1c)[1,2,3], postprandial glucose reduction[1,2,3], weight loss[1,2,3], systolic blood pressure reduction [1,2,3]and reducing the risk of hypoglycaemia during the treatment[1,2,3]. Treatment of type 1 diabetes is based on a model of intensive, functional insulin therapy with the use of human insulin preparations or analogues of this insulin[10].The therapy is carried out by multiple, subcutaneous injections of insulin doses or in the form of continuous insulin infusion with a personal insulin pump[10]. According to the recommendations of the Polish Diabetes Association(PTD)for patients with type 1 diabetes in terms of glycemic control, the primary goal is to maintain HbA1C7% (53mmol / mol) and when the goal is not associated with the risk of hypoglycaemia, the target value is6.5%.The use of proper treatment and sustaining HbA1C at the level recommended by PTD allows to prevent acute and chronic complications of the disease and at the same time allows patients to live actively and, consequently, improves their life quality [10]. According to recently published studies, preparations from SGLT-1 and SGLT-2 inhibitor groups may be helpful in obtaining and sustaining the treatment objective recommended by PTD. Keywords : SGLT-1 and SGLT-2 inhibitor, sotaglifosin, type 1 HbA1C diabetes, hypoglycaemia Keywords:SGLT1 and SGLT2 inhibitor, sotagliflozin, type 1 diabetes (T1D), HbA1C, hypoglycaemia